NeoGenomics Enters into National Agreement with Premier, Inc. to Offer Cancer Genetics Testing Services to 3,600 Hospitals

FT. MYERS, Fla., Sept. 2, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a national group purchasing agreement with Premier, Inc. Premier is a leading healthcare improvement company uniting an alliance of approximately 3,600 U.S. hospitals and 120,000 other providers, and is widely recognized as operating one of the largest healthcare group purchasing organizations (GPO) in the United States.

The three year agreement secures for NeoGenomics the distinction of becoming the first specialized oncology reference laboratory to become a preferred in-network lab option for all Premier member hospitals, cancer centers, pathology groups, and oncology/physician providers nationwide. 

The agreement is comprehensive in nature, and includes full access to the entire menu of oncology testing services offered by NeoGenomics, including NeoGenomics' industry-leading line of innovative and cost-effective NeoTYPE™ Cancer Profiles based on Next Generation Sequencing (NGS). These new advanced cancer-profiling tools offer oncologists and pathologists a more targeted and comprehensive ability to tailor cancer testing to an individual patient's needs than has ever been available before. 

Douglas VanOort, NeoGenomics' Chairman and Chief Executive Officer, stated, "We are extremely honored to have been selected by Premier to be their first specialized oncology reference lab.  Premier's membership includes more than half the hospitals in the United States and many important oncology and pathology practices that we believe will benefit from our full line of cancer genetic testing services."

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of CLIA–certified clinical laboratories that specialize in cancer genetics testing, the fastest growing segment of the laboratory industry.  The Company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.  NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States, and has laboratories in Nashville, TN; Irvine, Fresno and West Sacramento CA; and Tampa and Fort Myers, FL. 

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neogenomics-enters-into-national-agreement-with-premier-inc-to-offer-cancer-genetics-testing-services-to-3600-hospitals-300136546.html

SOURCE NeoGenomics, Inc.